|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
PETNET Solutions achieves 98.8 percent delivery rate for radioactive isotopes
|
|
Siemens Healthcare UK
: 25 September, 2008 (Company News) |
|
|
A division of Siemens, PETNET Solutions, has reported a 98.8 percent success rate in the production and delivery of its radioactive isotopes. |
|
The uptime rate ensures the safe production and delivery of its biomarkers to UK PET Scanner centres.
A reliable and efficient Biomarker service is vital to ensure the smooth running of diagnostic PET scans. The success of production and delivery means that PET centres can provide cancer patients with highly accurate scans that pinpoint the exact nature of disease. This includes information on how patients are responding to treatment as well as metastases. Without isotopes delivered in time, examinations have to be cancelled and patients may miss out on vital follow-up examinations.
The radioactive nature of PET biomarkers mean that PETNET Solutions must produce and deliver the vital pharmaceuticals before they decay. For example, the Biomarker MetaTrace FDG has a half-life of 110 minutes during which time it must be manufactured, QC tested, transported and delivered ready for use in diagnostic imaging. The service has to operate at maximum efficiency to produce the products and ensure they are on the road in time to get to the relevant destinations.
“We are very pleased that the results of this analysis indicate the reliability and efficiency of PETNET Solutions’ service,” said Ian Brown, business development manager for PETNET Solutions. “We are always striving to deliver the optimum service by improving the reliability of FDG deliveries. By providing biomarkers within a reliable timeframe we have ensured the trust of our customers and will continue to deliver a high quality service. We are also constantly expanding our research and development capabilities to offer further services and develop new biomarkers. We think this is important given the rapid developments in Molecular Imaging technology and the ever increasing weight of clinical evidence in support of PET. Recent well-publicised global shortages in the availability of Technetium (Tc-99) have demonstrated the fragility of supply of certain isotopes. PETNET Solutions offers alternative technologies which can help to mitigate these shortages both now and in the future.”
PETNET Solutions operates two PET manufacturing and distribution sites in the UK, one at Mount Vernon Hospital and the latest at Nottingham City Hospital.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
